Gilead Sciences’ shares soared 16% in after-hours trading Thursday following a media report detailing encouraging partial data from trials of the U.S. firm’s experimental drug remdesivir in severe COVID-19 patients.
A University of Chicago hospital taking part in a research of the antiviral remedy mentioned it’s seeing speedy recoveries in fever and respiratory symptoms, with almost all sufferers discharged in less than a week, in line with medical information web site ST.
Gilead, in an emailed assertion, stated: “the totality of the data should be analyzed in order to draw any conclusions from the trial.”
UChicago Medicine stated “partial data from an ongoing clinical trial is by definition incomplete and will never be used to draw conclusions.”
The university stated info from an internal discussion board for research colleagues regarding work in progress was revealed without authorization.
Gilead anticipates results from its Phase 3 study in sufferers with severe COVID-19 at the end of April, and additional data from other studies to become available in May.
The University of Chicago is one of 152 areas participating in Gilead’s trial involving severe COVID-19 sufferers, which is a single-arm that means it doesn’t measure the drug against a matched group of sufferers treated with a placebo.